In a phase 2 trial in head and neck squamous cell carcinoma, responses to the TLR9 agonist SD-101 occurred in both PD-L1 high and low tumors,104 suggesting benefits for patients who do not respond to ICIs due to low PD-L1 levels. The gene discussed is CD274; the disease is head and neck squamous cell carcinoma.